The short version
25 companies supply this market — deep enough that no single failure threatens the supply. The price has fallen 45% in a year, to $7.80 per mL — and generics that get this cheap tend to get abandoned rather than defended. One of its named manufacturing plants, Par Health USA, LLC, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Put together: worth watching — several of the pressures that precede supply trouble are present at once. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 4× the typical drug (0.1%).
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.